Singh Kuldev
Glaucoma Service, Stanford University, USA.
Open Ophthalmol J. 2009 Sep 17;3:65-6. doi: 10.2174/1874364100903020065.
Glaucoma care today is often simplified into all or nothing terms with the assumption that if the patient's intraocular pressure (IOP) is above a certain level, glaucomatous disease will progress and when the IOP is lowered to below a threshold, no further progression will occur. This dogma is largely the result of limitations in the resolution of tools currently available to judge progression. Glaucoma is a neurodegenerative disease and, as with all degenerative diseases, progression continues to occur, albeit at slower rates, with appropriate treatment. In the future, as our tools to assess structural and functional optic nerve change become more precise, we will no longer think of glaucoma as being stable or progressive but rather speak in terms of rates of progression.
如今,青光眼的治疗常常被简单地归结为非此即彼的情况,即假定如果患者的眼压(IOP)高于某一水平,青光眼疾病就会进展,而当眼压降至阈值以下时,就不会再发生进一步进展。这种教条很大程度上是由于目前用于判断病情进展的工具分辨率有限所致。青光眼是一种神经退行性疾病,与所有退行性疾病一样,即使经过适当治疗,病情仍会继续进展,尽管进展速度较慢。未来,随着我们评估视神经结构和功能变化的工具变得更加精确,我们将不再把青光眼视为稳定或进展性的,而是用进展速度来描述。